High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Items 301–400 of 1,001
Oncogene-induced Cellular Senescence
Chandeck, C., & Mooi, W. J. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181c66f4e · Cited by 116
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer
Nagasaka, M., Uddin, M. H., Hallak, M. N. A., Rahman, S. B., Balasubramanian, S. K., Sukari, A. W., & Azmi, A. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01371-1 · Cited by 124
Cutaneous melanoma susceptibility and progression genes
DESNOO, F., & Hayward, N. K. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.12.033 · Cited by 127
“NRAS mutations have been found at a frequency of w9% overall, in nevi of various histological types (Table 6), including compound [229], junctional [229], intradermal [228] and Spitz [224].”
BackgroundInfluentialSelf-citationPTEN functions as a melanoma tumor suppressor by promoting host immune response
Dong, Y., Richards, J.-A., Gupta, R., Aung, P. P., Emley, A., Kluger, Y., Dogra, S. K., Mahalingam, M., & Wajapeyee, N. (2014) · Oncogene · doi:10.1038/onc.2013.409 · Cited by 113
Weber, A., Hengge, U. R., Urbanik, D., Markwart, A., Mirmohammadsaegh, A., Reichel, M. B., Wittekind, C., Wiedemann, P., & Tannapfel, A. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000101732.89463.29 · Cited by 112
“Although mutations of the v-raf murine sarcoma viral homolog B1 (BRAF) have recently been described in approximately 66% of malignant cutaneous melanomas and 82% of melanocytic nevi (Davies et al, 2002), activating Ras and BRAF were also found in benign nevi (Pollock et al, 2003).”
BackgroundLarsen, A., Dahl, C., Dahmcke, C. M., Lade‐Keller, J., Siersma, V., Toft, P. B., Coupland, S. E., Prause, J. U., Guldberg, P., & Heegaard, S. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13007 · Cited by 112
“BRAF mutations have been reported with a high prevalence in conjunctival and cutaneous nevi, in conjunctival melanoma with origin in a nevus and in cutaneous melanoma associated with a preexisting nevus (Pollock et al. 2003; GoldenbergCohen et al. 2005; Edlundh-Rose et al. 2006; Griewank et al. 2013; Larsen et al. 201…”
InfluentialSharma, A., Tran, M. A., Liang, S., Sharma, A. K., Amin, S., Smith, C. D., Dong, C., & Robertson, G. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0809 · Cited by 112
Akslen, L. A., Angelini, S., Straume, O., Bachmann, I. M., Molven, A., Hemminki, K., & Kumar, R. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23788.x · Cited by 122
The dysplastic nevus: From historical perspective to management in the modern era
Duffy, K. L., & Grossman, D. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.03.013 · Cited by 120
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 148
RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors
Nakamura, N., Carney, J. A., Jin, L. G., Kajita, S., Pallarés, J., Zhang, H., Qian, X., Sebo, T. J., Erickson, L. A., & Lloyd, R. V. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700306 · Cited by 119
Noonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway
Tidyman, W. E., & Rauen, K. A. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000902 · Cited by 110
Current State of Animal (Mouse) Modeling in Melanoma Research
Kuzu, O. F., Nguyen, F. D., Noory, M. A., & Sharma, A. K. (2015) · Cancer Growth and Metastasis · doi:10.4137/cgm.s21214 · Cited by 138
GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi
Vader, M., Madigan, M. C., Versluis, M., Suleiman, H. M., Gezgin, G., Gruis, N. A., Out‐Luiting, J. J., Bergman, W., Verdijk, R. M., Jager, M. J., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.259 · Cited by 110
“We hypothesise that a choroidal nevus, as a potential precursor of UM, may already harbour clonal driver mutations, just as many cutaneous nevi are reported to present the typical V600E BRAF mutation associated with CM (Pollock et al, 2003; Shain et al, 2015).”
BackgroundEmerging molecular targets in melanoma invasion and metastasis
Orgaz, J. L., & Sanz‐Moreno, V. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12041 · Cited by 127
“Intriguingly, BRAF is also mutated in up to 80% of benign naevi (Pollock et al., 2003), even though most naevi stay indolent for decades and rarely progress to melanoma.”
BackgroundCooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
Nogueira, C., Kim, K.-H., Sung, H., Paraiso, K. H. T., Dannenberg, J.-H., Bosenberg, M., Chin, L., & Kim, M. (2010) · Oncogene · doi:10.1038/onc.2010.349 · Cited by 108
“Additionally, BRAF, a key effector of RAS signaling, is the most frequently mutated gene in human melanocytic neoplasms with frequencies of 82% of benign nevi and 66% in melanomas (Davies et al., 2002; Pollock et al., 2003).”
Katlinskaya, Y. V., Katlinski, K. V., Yu, Q., Ortiz, A., Beiting, D. P., Brice, A., Davar, D., Sanders, C., Kirkwood, J. M., Rui, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.006 · Cited by 108
“For example, mutagenic activation of BRAF and OIS markers are frequently found in benign melanocytic hyperplastic lesions (nevi) in humans (Dong et al., 2003; Pollock et al., 2003).”
BackgroundMechanisms of Drug Resistance in Melanoma
Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 127
SF3B1 and BAP1 mutations in blue nevus-like melanoma
Griewank, K., Müller, H., Jackett, L. A., Emberger, M., Möller, I., van de Nes, J. A. P., Zimmer, L., Livingstone, E., Wiesner, T., Scholz, S. L., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.23 · Cited by 110
Boursault, L., Haddad, V., Vergier, B., Cappellen, D., Verdon, S., Bellocq, J., Jouary, T., & Merlio, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070826 · Cited by 119
“A quite similar rate of BRAF activating mutations has been also found in melanocytic nevi [14][15].”
BackgroundUltraviolet radiation–induced DNA damage is prognostic for outcome in melanoma
Trucco, L. D., Mundra, P. A., Hogan, K., García-Martínez, P. L., Virós, A., Mandal, A. K., Macagno, N., Gaudy‐Marqueste, C., Allan, D., Baenke, F., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0265-6 · Cited by 120
Focus on cutaneous and uveal melanoma specificities
Pandiani, C., Béranger, G. E., Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Genes & Development · doi:10.1101/gad.296962.117 · Cited by 118
“It is noteworthy that these driver mutations do not necessarily translate into tumor induction, since NRAS and BRAFmutations are frequently found in congenital (Bauer et al. 2007) and common acquired (Pollock et al. 2003) nevi, respectively.”
BackgroundClonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia
Yeh, I., von Deimling, A., & Bastian, B. C. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt119 · Cited by 119
“Subsequent studies identified similar mutations in the majority of melanocytic nevi (82%), suggesting that BRAF mutations occur early during melanocytic transformation, possibly as an initiating event (1).”
BackgroundMC1R: Front and Center in the Bright Side of Dark Eumelanin and DNA Repair
Swope, V. B., & Abdel-Malek, Z. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092667 · Cited by 103
“It is noteworthy that this activating BRAF mutation is commonly expressed in nevi, some of which can be precursors to melanoma [36].”
BackgroundDirect targeting of Gα q and Gα 11 oncoproteins in cancer cells
Annala, S., Feng, X., Shridhar, N., Eryilmaz, F., Patt, J., Yang, J., Pfeil, E. M., Cervantes‐Villagrana, R. D., Inoue, A., Häberlein, F., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aau5948 · Cited by 110
“In contrast to CM, in which oncogenic mutations in the genes encoding B-Raf, N-Ras, or Kit are frequently found (42, 43), UM instead harbors mutually exclusive mutations at codon 209 in GNAQ and GNA11, two closely related genes that code for the subunits Gq and G11 of the heterotrimeric Gq family of proteins (44).”
BackgroundMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Palmieri, G., Ombra, M. N., Colombino, M., Casula, M., Sini, M. C., Manca, A., Paliogiannis, P., Ascierto, P. A., & Cossu, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00183 · Cited by 120
“However, the demonstration that BRAF is even mutated in common nevi (21) suggests that its oncogenic activation is necessary, but not sufficient, for the development of melanoma.”
BackgroundBUSAM, K. J., Hedvat, C. V., Pulitzer, M. P., von Deimling, A., & Jungbluth, A. A. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318271249e · Cited by 104
A Review of Epidemiology and Cancer Biology of Malignant Melanoma
Davey, M. G., Miller, N., & McInerney, N. M. (2021) · Cureus · doi:10.7759/cureus.15087 · Cited by 134
“BRAF mutations have been noted to be present in as many as 80% of benign naevi in human cutaneous tissue, resulting in limited melanocyte proliferation through the oncogene mediated activation of cell senescence [78,79].”
BackgroundGoding, C. R. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.10.003 · Cited by 123
Developmental pathways activated in melanocytes and melanoma
Liu, J., Fukunaga‐Kalabis, M., Li, L., & Herlyn, M. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.023 · Cited by 140
Genetics of metastasis: melanoma and other cancers
Turner, N., Ware, O. R., & Bosenberg, M. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9893-y · Cited by 110
Nevogenesis-New Thoughts Regarding a Classical Problem
Krengel, S. (2005) · American Journal of Dermatopathology · doi:10.1097/01.dad.0000175532.27368.3f · Cited by 103
Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
Kwong, L. N., & Davies, M. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0142 · Cited by 129
“In an immunohistochemical survey, PTEN protein loss was observed in melanoma but not in nevi (39), in contrast with the uniformly high mutation rate of BRAF across all stages (40).”
ResultMetabolic flexibility in melanoma: A potential therapeutic target
Ruocco, M. R., Avagliano, A., Granato, G., Vigliar, E., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.016 · Cited by 113
SKI activates Wnt/beta-catenin signaling in human melanoma.
Chen, D., Xu, W., Bales, E. S., Colmenares, C., Conacci‐Sorrell, M., Ishii, S., Stavnezer, E., Campisi, J., Fisher, D. E., Ben‐Ze'ev, A., et al. (2003) · PubMed · Cited by 112
Gast, A., Scherer, D., Chen, B., Bloethner, S., Melchert, S., Sucker, A., Hemminki, K., Schadendorf, D., & Kumar, R. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20785 · Cited by 110
“Nevertheless, overall data are overwhelmingly suggestive of involvement and requirement of additional genetic events in melanoma genesis (Pollock et al., 2003; Kumar et al., 2004; Akslen et al., 2008; Dhomen et al., 2009).”
BackgroundB-Raf and the inhibitors: from bench to bedside
Huang, T., Karsy, M., Zhuge, J., Zhong, M., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-30 · Cited by 100
“and primary melanoma, respectively [20].”
Resistance to Molecularly Targeted Therapies in Melanoma
Patel, M., Eckburg, A., Gantiwala, S., Hart, Z., Dein, J., Lam, K., & Puri, N. (2021) · Cancers · doi:10.3390/cancers13051115 · Cited by 111
“Over 80% of BRAF mutations are caused by a V600E amino acid substitution, while the remaining 20% of mutations consist mostly of V600K and V600D sub titut ons (Figure 2) [48,52].”
BackgroundRole of UV in Cutaneous Melanoma†
Maddodi, N., & Setaluri, V. (2008) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2007.00283.x · Cited by 101
Hypoxia and Senescence: The Impact of Oxygenation on Tumor Suppression
Welford, S. M., & Giaccia, A. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0065 · Cited by 108
“One clinical manifestation that would support this concept is themelanocytic nevus, a benign tumor ofmelanocytes that is filled with cells that frequently harbor a mutation in the BRaf gene (76).”
BackgroundThe dysplastic nevus: From historical perspective to management in the modern era
Duffy, K. L., & Grossman, D. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.02.047 · Cited by 127
Molecular Bases of Human Neurocristopathies
Etchevers, H., Amiel, J., & Lyonnet, S. (2007) · Springer eBooks · doi:10.1007/978-0-387-46954-6_14 · Cited by 117
Hafner, C. M., & Groesser, L. (2012) · Cell Cycle · doi:10.4161/cc.23108 · Cited by 98
Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
Haq, R., Fisher, D. E., & Widlund, H. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0898 · Cited by 105
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines
Tanami, H., Imoto, I., Hirasawa, A., Yuki, Y., Sonoda, I., Inoue, J., Yasui, K., Misawa-Furihata, A., Kawakami, Y., & Inazawa, J. (2004) · Oncogene · doi:10.1038/sj.onc.1208152 · Cited by 97
Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
Edmunds, S., Cree, I. A., Nicolantonio, F. D., Hungerford, J. L., Hurren, J., & Kelsell, D. P. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600919 · Cited by 97
“Mutations have also been detected in up to 82p of cutaneous melanocytic nevi (”
BackgroundTargeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Lo, H. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357970 · Cited by 102
Targeting MAPK pathway in melanoma therapy
Cheng, Y., Zhang, G., & Li, G. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9433-9 · Cited by 113
“Interestingly, BRAF mutations occurs in more than 80 % melanocytic nevi [81, 82], which are even more prevalent than in melanomas, suggesting that these genetic alterations are early events in melanoma development.”
BackgroundThe reactive oxygen‐driven tumor: relevance to melanoma
Fried, L., & Arbiser, J. L. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00451.x · Cited by 96
“B-raf, which lies upstream of MAP kinase, was found to be mutated in a large number of melanomas and later in nevi (Pollock and Meltzer, 2002; Pollock et al., 2003).”
BackgroundUnderstanding Signaling Cascades in Melanoma†
Lopez‐Bergami, P., Fitchman, B., & Ronai, Z. (2008) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2007.00254.x · Cited by 95
Pizzolanti, G., Russo, L., Richiusa, P., Bronte, V., Nuara, R. B., Rodolico, V., Amato, M. C., Smeraldi, L., Sisto, P. S., Nucera, M., et al. (2007) · Thyroid · doi:10.1089/thy.2007.0008 · Cited by 95
“Goiter (12) – – Adenoma (2) – – Hashimoto’s thyroiditis (1) – –”
The specificity of UVA-induced DNA damage in human melanocytes
Mouret, S., Forestier, A., & Douki, T. (2012) · Photochemical & Photobiological Sciences · doi:10.1039/c1pp05185g · Cited by 94
de Keizer, P. L. J., Packer, L. M., Szypowska, A. A., Riedl-Polderman, P. E., van den Broek, N. J. F., de Bruin, A., Dansen, T. B., Marais, R., Brenkman, A. B., & Burgering, B. M. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1563 · Cited by 94
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities
Eddy, K., Shah, R., & Chen, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626129 · Cited by 120
Greenwald, H. S., Friedman, E. B., & Osman, I. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834e6aa0 · Cited by 125
Anastasaki, C., Estep, A. L., Marais, R., Rauen, K. A., & Patton, E. E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp186 · Cited by 96
BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Hall, R. D., & Kudchadkar, R. R. (2014) · Cancer Control · doi:10.1177/107327481402100307 · Cited by 93
Premature cell senescence in human skin: Dual face in chronic acquired pigmentary disorders
Bellei, B., & Picardo, M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100981 · Cited by 93
Hafner, C. M., Toll, A., Fernández-Casado, A., Earl, J., Marqués, M., Acquadro, F., Méndez‐Pertuz, M., Urioste, M., Malats, N., Burns, J. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008365107 · Cited by 100
“The notion that nonneoplastic cells can harbor genetic mutations is not novel (9).”
BackgroundResultHear the Wnt Ror: how melanoma cells adjust to changes in Wnt
O’Connell, M. P., & Weeraratna, A. T. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00627.x · Cited by 93
Cancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma
Guan, J., Gupta, R., & Filipp, F. V. (2015) · Scientific Reports · doi:10.1038/srep07857 · Cited by 94
“In the context of melanoma, somatic splice-site mutation of TMEM216 suggests potential tumor suppressor function and sets the RHOA/GNA12 pathway apart from the G s -protein/MAPK pathway by mutual exclusivity of TMEM216 towards known oncogenes NRAS and RAC1 (Supplementary information 3).”
CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma
McNeal, A. S., Liu, K., Nakhate, V., Natale, C. A., Duperret, E. K., Capell, B. C., Dentchev, T., Berger, S. L., Herlyn, M., Seykora, J. T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0196 · Cited by 123
Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome
Siegel, D. H., McKenzie, J., Frieden, I. J., & Rauen, K. A. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10122.x · Cited by 99
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma
Zebary, A., Omholt, K., Vassilaki, I., Höiom, V., Lindén, D., Viberg, L., Kanter‐Lewensohn, L., Johansson, C. H., & Hansson, J. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.07.013 · Cited by 101
“The high frequency of BRAF and NRAS mutations in melanocytic nevi and the presence of these mutations in the radial growth phase indicate that BRAF and NRAS activation is an early event in the development of common melanoma subtypes [6–8], while involvement of these genes in the initiation and progression of ALMs is n…”
BackgroundBUSAM, K. J., Sung, J. J., Wiesner, T., von Deimling, A., & Jungbluth, A. A. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318263648c · Cited by 92
BRAF and NRAS mutations in spitzoid melanocytic lesions
Fullen, D. R., Poynter, J. N., Lowe, L., Su, L. D., Elder, J. T., Nair, R. P., Johnson, T. M., & Gruber, S. B. (2006) · Modern Pathology · doi:10.1038/modpathol.3800653 · Cited by 94
Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
Pritchard, A. L., & Hayward, N. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0383 · Cited by 112
Self-citationMechanisms of Cell-Cycle Arrest in Spitz Nevi with Constitutive Activation of the MAP-Kinase Pathway
Maldonado, J. L., Timmerman, L., Fridlyand, J., & Bastian, B. C. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63736-4 · Cited by 100
Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis
Ramaswamy, V., Delaney, H., Haque, S. S., Marghoob, A. A., & Khakoo, Y. (2012) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2012.04275.x · Cited by 91
Newman, S., Fan, L., Pribnow, A. K., Silkov, A., Rice, S. V., Lee, S., Shao, Y., Shaner, B., Mulder, H. L., Nakitandwe, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0373-y · Cited by 101
Detection of B-RAF and N-RAS mutations in human melanoma
Goydos, J. S., Mann, B., Kim, H. J., Gabriel, E. M., Alsina, J., Germino, J. F., Shih, W., & Gorski, D. H. (2005) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2004.10.032 · Cited by 91
BRAF Point Mutations in Primary Melanoma Show Different Prevalences by Subtype
Sasaki, Y., Niu, C., Makino, R., Kudo, C., Sun, C., Watanabe, H. K., Matsunaga, J., Takahashi, K., Tagami, H., Aiba, S., et al. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22722.x · Cited by 91
Role of BRAF‐V600E in the serrated pathway of colorectal tumourigenesis
Minoo, P., Moyer, M., & Jass, Jr. (2007) · The Journal of Pathology · doi:10.1002/path.2160 · Cited by 92
PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes
Larribère, L., Khaled, M., Tartare‐Deckert, S., Buscà, R., Luciano, F., Bille, K., Valony, G., Eychène, A., Auberger, P., Ortonne, J. ‐., et al. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401475 · Cited by 102
“sufficient by itself to promote melanocyte transformation and the characteristic resistance to apoptosis of the transformed cells.(39,40) These observations are in agreement with our”
ResultMutation analysis of B-RAF gene in human gliomas
Basto, D., Trovisco, V., Lopes, J. M., Martins, A. M., Pardal, F., Soares, P., & Reis, R. M. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0936-x · Cited by 90
“Although the oncogenic potential of RAF (particularly of C-RAF in in vitro models) has been known for a long time [15], it is only recently that a large-scale screen for genes mutated in cancer has reported the presence of somatic B-RAF mutations in human tumors, including melanomas, colorectal, lung and thyroid cance…”
BackgroundPERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development
Bu, Y., & Diehl, J. A. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25336 · Cited by 101
“BRAF/NRas mutations are the most common driver mutations in melanoma (Pollock et al., 2003).”
BackgroundKumar, R., Angelini, S., & Hemminki, K. (2003) · Oncogene · doi:10.1038/sj.onc.1206909 · Cited by 90
Could BRAF Mutations in Melanocytic Lesions Arise from DNA Damage Induced by Ultraviolet Radiation?
Thomas, N. E., Berwick, M., & Cordeiro‐Stone, M. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700458 · Cited by 104
“, 2002), their presence was reported in 20%–80% of melanocytic nevi in a variety of studies (Kumar et al., 2004; Pollock et al., 2003; Yazdi et al., 2003).”
BackgroundIGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways
Benatar, T., Yang, W., Amemiya, Y., Evdokimova, V., Kahn, H., Holloway, C., & Seth, A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1816-4 · Cited by 89
“protein 7 (IGFBP7) has been identified as a mediator of OIS in benign melanocytic nevi [1], the majority of which carry oncogenic mutations of BRAF or NRAS [2–4].”
BackgroundHacker, E., Hayward, N. K., Dumenil, T. D., James, M. R., & Whiteman, D. C. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.182 · Cited by 93
“, 2006) and commonly harbor BRAF V600 mutations (Pollock et al., 2003).”
BackgroundSelf-citationBorràs, E., Jurado, I., Hernán, I., Gamundi, M. J., Dias, M. M. D. S., Martí, I., Mañé, B., Arcusa, À., Agúndez, J. A. G., Blanca, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-406 · Cited by 95
“BRAF mutations are found in many types of cancer, predominantly in up to 80% of melanoma and nevi [12].”
BackgroundCD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation
Sharkey, M. S., Lizee, G. A., Gonzales, M. I., Patel, S. R., & Topalian, S. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3231 · Cited by 88
“Of note, the B-Raf V599E mutation is associated not only with melanomas but also with 82% of benign nevi (4), suggesting a role in carcinogenesis.”
BackgroundSchartl, M., Wilde, B., Laisney, J. A. G. C., Taniguchi, Y., Takeda, S., & Meierjohann, S. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.213 · Cited by 94
“, 2005), but presumably induces a senescence-like cell cycle arrest when present in nevi (Pollock et al., 2003).”
BackgroundCellular Senescence in the Development and Treatment of Cancer
Saretzki, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941874 · Cited by 87
Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress
Croft, A. J., Tay, K. H., Boyd, S. C., Guo, S., Jiang, C. C., Lai, F., Tseng, H., Jin, L., Rizos, H., Hersey, P., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.325 · Cited by 91
“Indeed, BRAF is found in the majority of nevi (Pollock et al., 2003; Michaloglou et al., 2005; Taube et al., 2009), and the UPR is activated at early stages of melanoma initiation by HRAS (Denoyelle et al.”
BackgroundDNA microarray analyses of melanoma gene expression: a decade in the mines
Hoek, K. S. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2007.00412.x · Cited by 100
Genetic similarities between Spitz nevus and Spitzoid melanoma in children
Gill, M., Cohen, J. A., Renwick, N. M., Mones, J. M., Silvers, D. N., & Celebi, J. T. (2004) · Cancer · doi:10.1002/cncr.20680 · Cited by 87
“Soon after these findings became known, 70 –90% of melanocytic nevi (junctional, compound, intradermal, congenital, and dysplastic nevi) also were found to have B-RAF mutations, suggesting a role for B-RAF in the early phase of melanocytic neoplasia.(12) The RAS genes (N-RAS, K-RAS, and H-RAS) and B-RAF serve as key s…”
BackgroundThe genetics of melanoma: recent advances
Hill, V. K., Gartner, J. J., Samuels, Y., & Goldstein, A. M. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153429 · Cited by 86
T1799A BRAF Mutations in Conjunctival Melanocytic Lesions
Goldenberg‐Cohen, N., Cohen, Y., Rosenbaum, E., Herscovici, Z., Chowers, I., Weinberger, D., Pe’er, J., & Sidransky, D. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-1449 · Cited by 86
Nicholas, C., Yang, J., Peters, S. B., Bill, M. A., Baiocchi, R. A., Yan, F., Sif, S., Tae, S., Gaudio, E., Wu, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074710 · Cited by 88
Etiologic Pathogenesis of Melanoma
Meyskens, F. L., Farmer, P. J., & Anton‐Culver, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0638 · Cited by 86
Michailidou, C., Jones, M., Walker, P., Kamarashev, J. A., Kelly, A., & Hurlstone, A. F. L. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.001149 · Cited by 96
“Activating BRAF mutations (particularly the valine for glutamate substitution at position 600) are believed to initiate the sequence of melanocyte neoplasia, since both common naevi and malignancies frequently (approximately 80% of cases) harbour such mutations (Pollock et al., 2003).”
BackgroundBRAF in Melanoma: Current Strategies and Future Directions
Salama, A. K. S., & Flaherty, K. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0779 · Cited by 91
“5 primary lesion could potentially be used, as there appears to be a high degree of concordance between primary lesions and metastases (9, 20-22).”
BackgroundActivation of the extracellular signal regulated kinase (ERK) pathway in human melanoma
Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S., Palmer, A. A., Zhang, X. D., Thompson, J. F., Bron, L. P., & Hersey, P. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.025957 · Cited by 85
Spitz nevi and other Spitzoid lesions
Luo, S., Sepehr, A., & Tsao, H. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.04.040 · Cited by 85
Dessars, B., Raeve, L. E. D., Housni, H. E., Debouck, C., Sidon, P. J., Morandini, R., Roseeuw, D. I., Ghanem, G., Vassart, G., & Heimann, P. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700725 · Cited by 84
“On the other hand, point mutations (especially the BRAFV600E mutation) are the main molecular mechanism of BRAF activation in both benign and malignant acquired melanocytic tumors (Davies et al., 2002; Pollock et al., 2003).”
BackgroundShahabi, V., Whitney, G. S., Hamid, O., Schmidt, H., Chasalow, S. D., Alaparthy, S., & Jackson, J. R. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1227-3 · Cited by 84
“This is consistent with the notion that the BRAF-V600E somatic mutation is an initiating event in the malignant transformation of melanomas and carried over from primary through metastatic disease [21, 22].”
BackgroundClonal Architectures and Driver Mutations in Metastatic Melanomas
Ding, L., Kim, M., Kanchi, K., Dees, N. D., Lu, C., Griffith, M., Fenstermacher, D., Sung, H., Miller, C. A., Goetz, B. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111153 · Cited by 91
“The driver mutations in BRAF and NRAS that have been identified cannot fully explain melanoma oncogenesis, as these same mutations have been found at similar rates in benign nevi, or moles [6,7].”
BackgroundIdentification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma
Bonazzi, V., Irwin, D. L., & Hayward, N. K. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20615 · Cited by 88
“, 2004) and benign melanocytic nevi (Dong et al., 2003; Pollock et al., 2003).”
BackgroundSelf-citationMethylation of PTEN as a Prognostic Factor in Malignant Melanoma of the Skin
Lahtz, C., Stranzenbach, R., Fiedler, E., Helmbold, P., & Dammann, R. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.226 · Cited by 95
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.